Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Second interchangeable biosimilar product approved by agency
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit
Subscribe To Our Newsletter & Stay Updated
